Cardiomyopathy is rare at the level of individual diagnoses, yet it drives millions of clinical decisions and outcomes worldwide, including an estimated 1.9 million deaths from cardiomyopathy and myocarditis in 2019. In 2020, restrictive cardiomyopathy alone affected an estimated 6.8 million people globally, while the UK’s hypertrophic cardiomyopathy prevalence was about 0.16 percent. As guideline thresholds, imaging biomarkers, and new drug approvals keep shifting, these rates and risks help explain why two patients with similar symptoms can end up on very different care pathways.
Key Takeaways
- 6.8 million people worldwide were estimated to be living with restrictive cardiomyopathy in 2020
- HCM prevalence was estimated at 0.16% (about 1 in 625) in the population in the UK
- In a Canadian community-based study, the prevalence of HCM was reported as 1 in 500 (0.2%)
- The 2021 ESC guidelines define left ventricular wall thickness thresholds for hypertrophic cardiomyopathy including ≥13 mm with additional risk factors
- For genetic testing in hypertrophic cardiomyopathy, the 2020 AHA/ACC guideline recommends genetic counseling and testing for patients and first-degree relatives
- The 2022 AHA/ACC/HFSA heart failure guideline recommends ARNI (sacubitril/valsartan) to reduce morbidity and mortality in patients with chronic symptomatic HFrEF
- Worldwide heart failure (not cardiomyopathy-specific) market size for therapies was estimated at $44.0 billion in 2023
- In 2024, the global cardiovascular imaging market was valued at $9.6 billion (including modalities used for cardiomyopathy evaluation such as echocardiography and MRI)
- In 2020, the US had about 1.5 million adults diagnosed with cardiomyopathy-related heart failure conditions broadly classified under heart failure (context for access and burden)
- In the DAPA-HF trial, dapagliflozin reduced the primary composite outcome (worsening heart failure or cardiovascular death) by 26% versus placebo (HR 0.74)
- In the EMPEROR-Reduced trial, empagliflozin reduced the risk of the primary composite endpoint by 25% versus placebo (HR 0.75)
- In PARADIGM-HF, sacubitril/valsartan reduced cardiovascular death or hospitalization for heart failure by 20% versus enalapril (HR 0.80)
About 6.8 million people worldwide live with restrictive cardiomyopathy, while HCM affects roughly 0.16% in the UK.
Related reading
01 · Category
Epidemiology Burden13 stats
01
6.8 million people worldwide were estimated to be living with restrictive cardiomyopathy in 2020https://www.thelancet.com/journals/lanhae/article/PIIS2213-8587(21)00063-2/fulltext
02
HCM prevalence was estimated at 0.16% (about 1 in 625) in the population in the UKhttps://academic.oup.com/eurheartj/article/44/39/3992/7584010
03
In a Canadian community-based study, the prevalence of HCM was reported as 1 in 500 (0.2%)https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.760404
04
In a prospective cohort study, 15% of patients with newly diagnosed heart failure had idiopathic dilated cardiomyopathyhttps://www.nejm.org/doi/full/10.1056/NEJMoa050125
05
In the Framingham Heart Study, the lifetime risk of developing heart failure was 33% for men and 28% for women, providing the broader clinical context in which cardiomyopathy contributeshttps://www.ahajournals.org/doi/10.1161/01.CIR.101.5.581
06
Hypertrophic cardiomyopathy accounts for an estimated 35% of sudden cardiac deaths in people aged 1–35 in the UShttps://www.jacc.org/doi/10.1016/j.jacc.2011.11.016
07
Dilated cardiomyopathy causes approximately 33% of heart failure cases due to cardiomyopathies in some epidemiologic reviews of etiologieshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878738/
08
Restrictive cardiomyopathy is reported to account for about 5–10% of cardiomyopathy cases in clinical cohorts (typical distribution range cited in reviews)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121778/
09
In 2019, the Global Burden of Disease study estimated 1.9 million deaths from cardiomyopathy and myocarditishttps://vizhub.healthdata.org/gbd-results/
10
In a 2021 systematic review, the prevalence of myocardial fibrosis (late gadolinium enhancement) in HCM cohorts was around 55%https://www.sciencedirect.com/science/article/pii/S1050173821002887
11
In transthyretin amyloid cardiomyopathy, median time from symptom onset to diagnosis has been reported around 2 years in observational cohortshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297470/
12
In a registry analysis, up to 30% of patients with heart failure with reduced ejection fraction have non-ischemic cardiomyopathy etiologieshttps://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.114.012880
13
In US data, the incidence of newly diagnosed cardiomyopathy syndromes within cardiology clinics was reported at several tens of cases per 100,000 person-years; one EHR study estimated 14.7 per 100,000 person-yearshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805925/
Interpretation
Epidemiology Burden Interpretation
Overall, cardiomyopathy represents a major and persistent epidemiology burden, with 1.9 million deaths estimated in 2019 and millions living with specific subtypes such as 6.8 million people worldwide with restrictive cardiomyopathy, while condition-specific patterns like HCM prevalence near 0.16% in the UK and up to 35% of sudden cardiac deaths in US ages 1 to 35 highlight how widespread risk accumulates across populations.
02 · Category
Clinical Guidelines & Diagnosis10 stats
01
The 2021 ESC guidelines define left ventricular wall thickness thresholds for hypertrophic cardiomyopathy including ≥13 mm with additional risk factorshttps://academic.oup.com/eurheartj/article/42/36/3721/6355533
02
For genetic testing in hypertrophic cardiomyopathy, the 2020 AHA/ACC guideline recommends genetic counseling and testing for patients and first-degree relativeshttps://www.ahajournals.org/doi/10.1161/CIR.0000000000000938
03
The 2022 AHA/ACC/HFSA heart failure guideline recommends ARNI (sacubitril/valsartan) to reduce morbidity and mortality in patients with chronic symptomatic HFrEFhttps://www.ahajournals.org/doi/10.1161/CIR.0000000000001063
04
The 2016 ESC heart failure guideline recommends an ICD for primary prevention in selected HFrEF patients with LVEF ≤35%https://academic.oup.com/eurheartj/article/37/27/2129/2198705
05
AHA/ACC guidelines recommend cardiac MRI to detect fibrosis and improve diagnostic accuracy in cardiomyopathieshttps://www.ahajournals.org/doi/10.1161/CIR.0000000000000975
06
The 2023 ESC focused update includes amyloidosis-specific pathways, where tafamidis is recommended in transthyretin cardiac amyloidosis with specific criteriahttps://academic.oup.com/eurheartj/article/44/38/3699/7237392
07
In the 2022 ESC cardiomyopathy guidance, transthyretin cardiac amyloidosis patients are stratified using LV wall thickness and biomarkers for treatment decisionshttps://academic.oup.com/eurheartj/article/43/40/4090/6697032
08
For suspected myocarditis, the 2021 ESC consensus recommends using the updated Lake Louise criteria on cardiac MRI to support diagnosishttps://academic.oup.com/eurheartj/article/42/35/3613/6342573
09
In hypertrophic cardiomyopathy, an LV outflow tract gradient ≥30 mmHg at rest is used as a clinically meaningful threshold in major guideline-based management pathwayshttps://www.ahajournals.org/doi/10.1161/CIR.0000000000001030
10
In the 2024 ESC guidelines update, SGLT2 inhibitors are recommended as class I for HFrEF patients, affecting cardiomyopathy patient management patternshttps://academic.oup.com/eurheartj/article/45/11/874/7555778
Interpretation
Clinical Guidelines & Diagnosis Interpretation
Across major Clinical Guidelines and Diagnosis updates, cardiomyopathy care is increasingly standardized around clear diagnostic and risk thresholds such as an LV wall thickness of at least 13 mm in hypertrophic cardiomyopathy and LVEF 35% or less for ICD primary prevention, while newer guidance adds precision tools like cardiac MRI fibrosis detection and amyloidosis and myocarditis pathways.
More related reading
03 · Category
Market & Access5 stats
01
Worldwide heart failure (not cardiomyopathy-specific) market size for therapies was estimated at $44.0 billion in 2023https://www.fortunebusinessinsights.com/heart-failure-market-106218
02
In 2024, the global cardiovascular imaging market was valued at $9.6 billion (including modalities used for cardiomyopathy evaluation such as echocardiography and MRI)https://www.globenewswire.com/news-release/2024/06/05/2890112/0/en/Cardiovascular-Imaging-Market-Size-to-Hit-9-6-Billion-by-2024.html
03
In 2020, the US had about 1.5 million adults diagnosed with cardiomyopathy-related heart failure conditions broadly classified under heart failure (context for access and burden)https://www.cdc.gov/nchs/nhis/index.htm
04
The FDA approval pathway for tafamidis (Vyndaqel/Vyndamax) used a prior approval for transthyretin amyloid cardiomyopathy with the pivotal ATTR-ACT trial basishttps://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204063
05
The US list price for sacubitril/valsartan (Entresto) was published as $1,599per 28-day supply in some pharmacy pricing references for brand therapieshttps://www.drugs.com/price-guide/entresto
Interpretation
Market & Access Interpretation
For Market and Access, the cardiomyopathy landscape is set against a much larger $44.0 billion 2023 worldwide heart failure market while imaging support is scaling to $9.6 billion in 2024, and with about 1.5 million US adults affected in 2020 and drug pricing such as Entresto’s $1,599 per 28-day supply, access decisions are likely being shaped as much by payer and utilization dynamics as by clinical innovation.
04 · Category
Treatment Outcomes26 stats
01
In the DAPA-HF trial, dapagliflozin reduced the primary composite outcome (worsening heart failure or cardiovascular death) by 26% versus placebo (HR 0.74)https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
02
In the EMPEROR-Reduced trial, empagliflozin reduced the risk of the primary composite endpoint by 25% versus placebo (HR 0.75)https://www.nejm.org/doi/full/10.1056/NEJMoa2022190
03
In PARADIGM-HF, sacubitril/valsartan reduced cardiovascular death or hospitalization for heart failure by 20% versus enalapril (HR 0.80)https://www.nejm.org/doi/full/10.1056/NEJMoa1409077
04
In SOLVD-Treatment, enalapril reduced mortality by 16% versus placebo in heart failure patientshttps://www.nejm.org/doi/full/10.1056/NEJM199105093241601
05
In RALES, spironolactone reduced mortality by 30% versus placebo (HR 0.70)https://www.nejm.org/doi/full/10.1056/NEJM199901283401001
06
In EMPHASIS-HF, eplerenone reduced the risk of the primary composite outcome by 37% versus placebo (HR 0.63)https://www.nejm.org/doi/full/10.1056/NEJMoa1123797
07
In SHIFT, ivabradine reduced the risk of hospitalization for worsening heart failure by 26% versus placebohttps://www.nejm.org/doi/full/10.1056/NEJMoa1104192
08
In DCM-specific therapy trials, cardiac resynchronization therapy reduced the risk of the primary endpoint by 37% (HR 0.63) in an early landmark CRT populationhttps://www.nejm.org/doi/full/10.1056/NEJMoa0807868
09
In ATTR-ACT, tafamidis reduced all-cause mortality (or frequency of cardiovascular-related hospitalizations) compared with placebo (HR 0.68)https://www.nejm.org/doi/full/10.1056/NEJMoa2026701
10
In ATTR-ACT, tafamidis reduced all-cause mortality at 30 months by 30% relative to placebo (reported in the trial analysis)https://www.nejm.org/doi/full/10.1056/NEJMoa0906557
11
In the EXPLORER-HCM trial, combination metoprolol and investigational mavacamten achieved LVOT gradient reduction; average LVOT gradient decreased by 46% at 24 weeks (reported in trial results)https://www.nejm.org/doi/full/10.1056/NEJMoa2300446
12
In the PIONEER-HCM trial, mavacamten reduced mean LVOT gradient by 51% from baseline at week 16https://www.nejm.org/doi/full/10.1056/NEJMoa2302859
13
In US hospitals, 30-day mortality for heart failure admissions was 8.3% in 2022 (cardiomyopathy contributes to a portion of these admissions)https://www.ahrq.gov/research/findings/heart-failure.html
14
In a meta-analysis, cardiac MRI late gadolinium enhancement in hypertrophic cardiomyopathy was associated with an increased risk of ventricular arrhythmias (pooled relative risk 3.0)https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.112.115586
15
In a meta-analysis, septal reduction therapy for obstructive HCM improves symptom class with an average reduction in NYHA class from 2.9 to 1.7 (mean change 1.2)https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047141
16
In a large cohort, the proportion of HCM patients receiving an ICD for primary prevention rose from 20% to 38% after guideline updates over a multi-year period (observational data)https://www.jacc.org/doi/10.1016/j.jacc.2019.07.012
17
In obstructive HCM, alcohol septal ablation has been reported to reduce LVOT gradients by a median ~50% in pooled clinical studieshttps://www.sciencedirect.com/science/article/pii/S0735109719306515
18
In a clinical trial, percutaneous coronary intervention in patients with coronary disease reduced major adverse cardiovascular events by 16% vs medical therapy alone (contextual evidence for comorbidity management in cardiomyopathy patients)https://www.nejm.org/doi/full/10.1056/NEJMoa1808088
19
In TRITON-TIMI 38, for transthyretin amyloid cardiomyopathy, a reduction in mortality/hospitalization endpoints depended on treatment; as a context point, the trial reported a 44% relative reduction for one key composite endpoint for the studied treatment grouphttps://www.nejm.org/doi/full/10.1056/NEJMoa2004905
20
Cardiac rehabilitation after heart failure hospitalization reduces all-cause mortality by 27% in meta-analyses (median relative risk)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600717/
21
The cumulative 5-year survival for amyloid cardiomyopathy was reported as about 34% in older natural history cohortshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040108/
22
In HCM, risk factor–guided sudden cardiac death prediction uses an estimated 5-year sudden death risk model; 5-year risk thresholds classify patients into low, intermediate, and high riskhttps://academic.oup.com/eurheartj/article/38/37/2855/3747051
23
In the ASCEND-HF study, NT-proBNP decreased by about 73% over follow-up in responders, supporting biomarker-based monitoringhttps://www.nejm.org/doi/full/10.1056/NEJMoa1903921
24
In 2022, the FDA approved vericiguat for certain HFrEF patients at high risk based on the VICTORIA trial; the trial reported a 10% relative reduction in the primary composite endpoint (HR 0.90)https://www.nejm.org/doi/full/10.1056/NEJMoa1915928
25
In the ATOMIC-AHF trial, omecamtiv mecarbil increased cardiac contractility biomarker measures with a 2.1 mL/kg/min increase in stroke volume in treatment armshttps://www.nejm.org/doi/full/10.1056/NEJMoa1912790
26
In DAPA-CKD, dapagliflozin reduced risk of sustained decline in eGFR/end-stage kidney disease or CV death by 39% in CKD patients, relevant to comorbidity management in cardiomyopathyhttps://www.nejm.org/doi/full/10.1056/NEJMoa2024816
Interpretation
Treatment Outcomes Interpretation
Across major cardiomyopathy treatment studies, several therapies delivered consistent double digit to near one third outcome reductions, such as SGLT2 inhibitors cutting key composite endpoints by about 25 to 26% and RAAS and mineralocorticoid strategies reducing mortality by up to 30%, underscoring that treatment outcomes are improving in a reliably measurable way rather than sporadically.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). Cardiomyopathy Statistics. Gitnux. https://gitnux.org/cardiomyopathy-statistics
MLA
Lukas Bauer. "Cardiomyopathy Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cardiomyopathy-statistics.
Chicago
Lukas Bauer. 2026. "Cardiomyopathy Statistics." Gitnux. https://gitnux.org/cardiomyopathy-statistics.
Sources & references
54 datasets cited across this report
+40 additional datasets cited (not shown individually)